Year All202420232022202120202019 Mar 02, 2023 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results Feb 14, 2023 Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia Jan 03, 2023 Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference Nov 11, 2022 Verve Therapeutics to Participate in Upcoming Investor Conferences Nov 07, 2022 Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results Oct 31, 2022 Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting Sep 22, 2022 Verve Therapeutics to Participate in Upcoming Investor Conferences Sep 21, 2022 Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Aug 22, 2022 Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress Aug 09, 2022 Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
Mar 02, 2023 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 14, 2023 Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
Nov 07, 2022 Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
Oct 31, 2022 Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
Sep 21, 2022 Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Aug 22, 2022 Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress
Aug 09, 2022 Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
